Peripheral T-cell lymphomas expressing CD30
assessment is recommended because of the potential utility of the anti-CD30
antibody-drug conjugate brentuximab vedotin.
Brentuximab binds and is internalized by cells that express the CD30
antigen; subsequently, MMAE causes cell cycle arrest and apoptosis .
Based on immunohistologic characteristics of strong CD30
positivity, coexpression with CD3/CD4 antigens, light EMA positivity, CD20 and Alk-1 negativity, and 15% Ki-67 proliferation rate with no apparent cells of the Reed-Sternberg morphology, possibility of a peripheral T-cell lymphoma was considered.
Immunostaining revealed LCA, CD30
and CD3 Positive while ALK was negative.
Brentuximab vedotin is a type of monoclonal antibody that targets a protein called CD30
that is found on Hodgkin's lymphoma cells and anaplastic large cell lymphoma (ALCL) cells.
All the cases were positive for CD30
while 23 (92%) cases for CD3, 22 (88 %) cases for ALK and 19 (76%) cases positive for EMA.
Expression of epithelial membrane antigen and CD30
are frequently seen.
To determinate, relationship between variations of CD30
marker expressed in cancerous cells and clonality rates, the Pearson's chi-square ([chi square] test) and Fisher's exact tests were performed.
Expression of CD30
(an activation marker for B or T cells) in more than 75% of neoplastic cells characterizes this group of lympho-proliferative disorders.
Immunohistokimyasal incelemede lenfosit lerde CD20 ve CD3 antijenlerinin pozitif oldugu ve seyrek olarak CD30
ile pozitif reaktivite veren aktive lenfositler goruldu.
molecule, a member of the TNF superfamily of membrane cytokine receptors, is expressed by activated CD4+T cells predominantly producing Th2 type cytokines in vitro (8).